SK76695A3 - Expression system for producing apolipoprotein ai-m - Google Patents

Expression system for producing apolipoprotein ai-m Download PDF

Info

Publication number
SK76695A3
SK76695A3 SK766-95A SK76695A SK76695A3 SK 76695 A3 SK76695 A3 SK 76695A3 SK 76695 A SK76695 A SK 76695A SK 76695 A3 SK76695 A3 SK 76695A3
Authority
SK
Slovakia
Prior art keywords
apolipoprotein
escherichia coli
expression vector
cultivation
temperature
Prior art date
Application number
SK766-95A
Other languages
English (en)
Slovak (sk)
Inventor
Lars Abrahmsen
Erik Holmgren
Christina Kalderen
Mats Lake
Asa Mikaelsson
Torsten Sejlitz
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of SK76695A3 publication Critical patent/SK76695A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/71—Expression systems using regulatory sequences derived from the trp-operon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
SK766-95A 1992-12-11 1993-12-09 Expression system for producing apolipoprotein ai-m SK76695A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9203753A SE9203753D0 (sv) 1992-12-11 1992-12-11 Expression system for producing apolipoprotein ai-m
PCT/SE1993/001061 WO1994013819A1 (en) 1992-12-11 1993-12-09 Expression system for producing apolipoprotein ai-m

Publications (1)

Publication Number Publication Date
SK76695A3 true SK76695A3 (en) 1996-02-07

Family

ID=20388112

Family Applications (1)

Application Number Title Priority Date Filing Date
SK766-95A SK76695A3 (en) 1992-12-11 1993-12-09 Expression system for producing apolipoprotein ai-m

Country Status (22)

Country Link
US (1) US5721114A (el)
EP (1) EP0677109B1 (el)
JP (1) JP3899121B2 (el)
AT (1) ATE191930T1 (el)
AU (1) AU5663794A (el)
CA (1) CA2150928C (el)
CZ (1) CZ290865B6 (el)
DE (1) DE69328442T2 (el)
DK (1) DK0677109T3 (el)
ES (1) ES2146646T3 (el)
FI (1) FI952847A (el)
GR (1) GR3033966T3 (el)
HU (1) HU220193B (el)
IL (1) IL107896A (el)
MX (1) MX9307855A (el)
NO (1) NO319497B1 (el)
PL (1) PL175955B1 (el)
PT (1) PT677109E (el)
SE (1) SE9203753D0 (el)
SK (1) SK76695A3 (el)
WO (1) WO1994013819A1 (el)
ZA (1) ZA939266B (el)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500778D0 (sv) 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
EP0871713B1 (en) * 1995-11-09 2007-02-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES The use of lecithin-cholesterol acyltransferase (lcat) in the treatment of atherosclerosis
SE9603068D0 (sv) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
US6306433B1 (en) 1997-08-12 2001-10-23 Pharmacia Ab Method of preparing pharmaceutical compositions
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
CN1297932A (zh) * 1999-11-30 2001-06-06 上海博容基因开发有限公司 一种新的多肽——人脂蛋白前体蛋白信号肽11和编码这种多肽的多核苷酸
US20020064820A1 (en) * 2000-03-13 2002-05-30 Jean-Michel Dayer Apo-A-I regulation of T-cell signaling
CA2428114C (en) 2000-11-10 2013-07-23 Proteopharma Aps Apolipoprotein analogues
US7217785B2 (en) 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
MXPA04002848A (es) * 2001-09-28 2005-06-06 Esperion Therapeutics Inc Prevencion y tratamiento de restenosis por administracion local de medicamento.
JP2005511713A (ja) * 2001-12-07 2005-04-28 ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア 加齢性黄斑変性についての処置
US20030229062A1 (en) * 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
US7470659B2 (en) 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
US7223726B2 (en) * 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
US7691965B2 (en) * 2002-05-08 2010-04-06 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
US20100204103A1 (en) * 2002-05-08 2010-08-12 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
WO2003096983A2 (en) 2002-05-17 2003-11-27 Esperion Therapeutics, Inc. Method of treating dyslipidemic disorders
NZ537006A (en) * 2002-05-17 2008-01-31 Esperion Therapeutics Inc The use of apolipoprotein A-I Milano, for the manufacture ofa composition for treating preventing or reducing ischemic reperfusion injury in a tissue or organ
MX349134B (es) 2003-01-23 2017-07-12 Esperion Therapeutics Inc Compuestos de hidroxilo y composiciones para el manejo del colesterol y usos relacionados.
WO2004078965A1 (ja) * 2003-03-05 2004-09-16 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 大腸菌における異種蛋白質の製造方法
WO2005097206A2 (en) * 2004-04-06 2005-10-20 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein a-i and apolipoprotein a-i milano
KR100560102B1 (ko) 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
CN1320119C (zh) * 2004-12-09 2007-06-06 复旦大学 人载脂蛋白ApoAⅠ在毕赤氏酵母胞内表达的方法
CA2620065C (en) 2005-08-22 2011-03-29 Melior Discovery, Inc. Methods and formulations for modulating lyn kinase activity and treating related disorders
US20070048823A1 (en) * 2005-08-26 2007-03-01 Cerenis Therapeutics, S.A. Compositions and Methods for Producing Apolipoprotein Gene Products in Lactic Acid Bacteria
DE102006004871A1 (de) 2006-02-02 2007-08-09 Wacker Chemie Ag Mikroorganismenstamm zur Produktion von rekombinanten Proteinen
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
EP2537526A1 (en) 2006-06-01 2012-12-26 Institut de Cardiologie de Montréal Method and compound for the treatment of valvular stenosis
DE502006009060D1 (de) 2006-09-22 2011-04-21 Wacker Chemie Ag Verfahren zur fermentativen Herstellung von Antikörpern
DE102006044841A1 (de) 2006-09-22 2008-04-03 Wacker Chemie Ag Signalpeptid zur Produktion von rekombinanten Proteinen
DE102006050332A1 (de) 2006-10-25 2008-04-30 Wacker Chemie Ag DNS-Konstrukt und Verfahren zur fermentativen Herstellung von Fusionsproteinen
CA2931881C (en) * 2007-01-31 2018-12-11 Nutrition 21, Inc. Use of chromium histidinate for treatment of cardiometabolic disorders
MX2009008874A (es) * 2007-02-20 2009-10-20 Melior Pharmaceuticals I Inc Metodos para identificar activadores de cinasa lyn.
CA2681158C (en) 2007-03-13 2018-09-18 Nutrition 21, Inc. Methods and compositions for the sustained release of chromium
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
WO2009015133A1 (en) * 2007-07-23 2009-01-29 Melior Discovery, Inc. Methods of activating irs-1 and akt
US8143224B2 (en) * 2007-10-23 2012-03-27 The Cleveland Clinic Foundation Oxidant resistant apolipoprotein A-1 and mimetic peptides
US8552184B2 (en) * 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
KR20220150995A (ko) 2008-11-10 2022-11-11 알닐람 파마슈티칼스 인코포레이티드 치료제 운반용 신규 지질 및 조성물
EP3243504A1 (en) 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Improved lipid formulation
RU2532222C2 (ru) 2009-02-16 2014-10-27 Серенис Терапьютикс Холдинг С.А, Миметики аполипопротеина а-i
EP2406376A1 (en) 2009-03-12 2012-01-18 Alnylam Pharmaceuticals, Inc. LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
SG10201402054UA (en) 2009-05-05 2014-09-26 Muthiah Manoharan Lipid compositions
TR201811076T4 (tr) 2009-06-10 2018-08-27 Arbutus Biopharma Corp Geliştirilmiş lipit formulasyonu.
EP2810643A3 (en) 2009-08-14 2015-03-11 Alnylam Pharmaceuticals Inc. Lipid formulated compositions and mehods for inhibiting expression of a gene from the ebola virus
DE102009053566B4 (de) 2009-11-11 2014-08-14 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Mikroorganismen mit gesteigerter Sucrosemutaseaktivität
EP2509636B1 (en) 2009-12-07 2017-07-19 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
CA2784568A1 (en) 2009-12-18 2011-06-23 Martin A. Maier Lipid particles for delivery of nucleic acids
US20130156845A1 (en) 2010-04-29 2013-06-20 Alnylam Pharmaceuticals, Inc. Lipid formulated single stranded rna
US20130137628A1 (en) 2010-05-11 2013-05-30 Esperion Therapeutics, Inc. Dimeric Oxidation-Resistant Apolipoprotein A1 Variants
WO2011150300A1 (en) 2010-05-28 2011-12-01 Melior Pharmaceuticals I, Inc. Prevention of pancreatic beta cell degeneration
CN103096875B (zh) 2010-06-03 2016-08-17 阿尔尼拉姆医药品有限公司 用于递送活性剂的生物可降解脂质
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
BR112013004396A2 (pt) * 2010-08-30 2016-05-17 Hoffmann La Roche alimentação alcalina
US9339513B2 (en) 2010-11-09 2016-05-17 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
DK2663548T3 (en) 2011-01-11 2017-07-24 Alnylam Pharmaceuticals Inc PEGYLED LIPIDS AND THEIR USE FOR PHARMACEUTICAL SUPPLY
RU2017126088A (ru) 2011-02-07 2019-01-31 Серени Терапеутикс Холдинг С.А. Липопротеиновые комплексы и их получение и применения
MX344925B (es) 2011-03-01 2017-01-11 N21 Acquisition Holding Llc Composiciones de insulina y cromo para el tratamiento y prevención de diabetes, hipoglucemia y alteraciones relacionadas.
EP2760477B1 (en) 2011-09-27 2018-08-08 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted pegylated lipids
RU2646475C2 (ru) 2011-12-12 2018-03-05 МЕЛИОР ФАРМАСЬЮТИКАЛЗ Ай, ИНК. Лечение диабета I и II типа
WO2014011908A1 (en) 2012-07-11 2014-01-16 Esperion Therapeutics, Inc. Apolipoprotein mixtures
BR112016025470A2 (pt) 2014-05-02 2017-08-15 Cerenis Therapeutics Holding S A ?hdl terapêutico?
US11865121B2 (en) 2016-02-11 2024-01-09 Nutrition21, LLC Chromium containing compositions for improving health and fitness
US10426817B2 (en) * 2017-01-24 2019-10-01 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics
SG11201909406VA (en) 2017-04-10 2019-11-28 Melior Pharmaceuticals I Inc Treatment of adipocytes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
EP0345155B1 (en) * 1988-05-31 1994-08-10 Mitsubishi Kasei Corporation Process for producing natural human apolipoprotein e-like proteins
DE3819463A1 (de) * 1988-06-08 1989-12-14 Behringwerke Ag Expressionsvektoren zur herstellung unfusionierter proteine in mikroorganismen
US5223407A (en) * 1988-08-31 1993-06-29 Allelix Inc. Excretion of heterologous proteins from e. coli
IT1229996B (it) * 1989-04-20 1991-09-20 Cesare Sirtori Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
EP0497757B1 (en) * 1989-10-31 1994-06-22 Schering Corporation E. coli secretory strains
DE4009268A1 (de) * 1990-03-22 1991-09-26 Consortium Elektrochem Ind Sekretion von hirudinderivaten
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein

Also Published As

Publication number Publication date
CZ148795A3 (en) 1996-01-17
JPH08506723A (ja) 1996-07-23
SE9203753D0 (sv) 1992-12-11
ZA939266B (en) 1994-08-08
PT677109E (pt) 2000-07-31
IL107896A (en) 2004-06-01
AU5663794A (en) 1994-07-04
JP3899121B2 (ja) 2007-03-28
HU220193B (hu) 2001-11-28
CA2150928C (en) 2005-02-08
EP0677109A1 (en) 1995-10-18
DK0677109T3 (da) 2000-07-17
CA2150928A1 (en) 1994-06-23
DE69328442T2 (de) 2000-09-07
FI952847A0 (fi) 1995-06-09
ATE191930T1 (de) 2000-05-15
US5721114A (en) 1998-02-24
CZ290865B6 (cs) 2002-11-13
EP0677109B1 (en) 2000-04-19
ES2146646T3 (es) 2000-08-16
NO319497B1 (no) 2005-08-22
FI952847A (fi) 1995-06-09
PL309292A1 (en) 1995-10-02
HUT71697A (en) 1996-01-29
MX9307855A (es) 1994-06-30
NO952297L (no) 1995-06-09
IL107896A0 (en) 1994-04-12
WO1994013819A1 (en) 1994-06-23
GR3033966T3 (en) 2000-11-30
HU9501680D0 (en) 1995-08-28
PL175955B1 (pl) 1999-03-31
NO952297D0 (no) 1995-06-09
DE69328442D1 (de) 2000-05-25

Similar Documents

Publication Publication Date Title
SK76695A3 (en) Expression system for producing apolipoprotein ai-m
JP5634971B2 (ja) 培地へのペプチドの直接発現
KR101299417B1 (ko) 카복시-말단 아미드화 펩티드를 제조하는 방법
JP5591447B2 (ja) ペプチドを直接発現させるための改良型細菌宿主細胞
US5028530A (en) AraB promoters and method of producing polypeptides, including cecropins, by microbiological techniques
CA2145388C (en) Method of controlling polypeptide production in bacteria
US5206154A (en) Method of producing cecropins by microbiological techniques
KR100316347B1 (ko) 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법
EP2173768B1 (en) Novel orthogonal process for purification of recombinant human parathyroid hormone (rhpth) (1-34)
US20080293102A1 (en) Compositions and methods for producing apolipoprotein
EP0460709B1 (en) AraB promoters and method of producing polypeptides, including cecropins, by microbiological techniques
JP2001008697A (ja) Ｅ．コリでの非融合タンパク質の調製方法
WO2001044469A1 (fr) PROCEDE DE PRODUCTION DE PEPTIDE KiSS-1
JPH08503376A (ja) 細菌内の異種遺伝子の発現の間の内因性アミノペプチダーゼ媒介ｎ−末端アミノ酸開裂の防止
JPH08103279A (ja) 組換え人ミオグロビンの製造方法
CN111848774A (zh) 一种美曲普汀的制备方法
HU230335B1 (hu) Eljárás polipeptidek előállítására
EP0578754B1 (en) TrpR MUTATIONS EFFECTIVE IN THE EXPRESSION OF SMALL PROTEINS AND PEPTIDES
Trepod et al. Modification of the carboxy-terminal amino acid sequence alters the Escherichia coli expression of a gene encoding multiple repeats of a bovine growth hormone releasing factor analog
JP2020058343A (ja) フコース結合性タンパク質の製造方法
JPS60501989A (ja) インシュリン様成長因子の微生物発現
WO2012133119A1 (ja) フェリチンの製造方法
WO1986006410A1 (en) Process for increasing yield of interleukin-2